Study of Eltrombopag in Platelet Refractory Thrombocytopenia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2010-08-31

Study Completion Date

2012-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase II trial is studying the effects of the drug eltrombopag has on thrombocytopenia (low platelet count). Eltrombopag is approved by the FDA for the treatment of thrombocytopenia (low platelet count) in adults who have had an insufficient response to medications such as corticosteroids and immunoglobulins. Eltrombopag is not approved by the FDA (Food and Drug Administration) for the treatment of thrombocytopenia refractory to platelet transfusion and so for this study is considered investigational.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia

NCT01286038

Myelodysplastic Syndrome (MDS) Thrombocytopenia

TERMINATED PHASE1

Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia.

NCT01791101

Thrombocytopenia

COMPLETED PHASE2

Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma

NCT01484314

Thrombocytopenia Multiple Myeloma

TERMINATED PHASE2

Safety and Efficacy of Eltrombopag at Escalated Doses

NCT01880047

Immune Thrombocytopenia Platelet Disorder

COMPLETED PHASE2

Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.

NCT01520909

Idiopathic Thrombocytopenic Purpura

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thrombocytopenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Eltrombopag

Eltrombopag 75 mg per day. Possible escalation to 150 mg per day after day 15 lab results. Possible escalation to 300 mg per day after day 29 lab results.

Group Type EXPERIMENTAL

Eltrombopag

Intervention Type DRUG

75 mg per day with possible dose escalation to 150 mg per day and 300 mg per day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Eltrombopag

75 mg per day with possible dose escalation to 150 mg per day and 300 mg per day

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Laboratory diagnosis of platelet refractoriness
* Diagnosis of platelet dependence
* Adequate liver and renal laboratory screening tests

Exclusion Criteria

* Patients with thrombocytopenia that are responsive to platelet therapy
* Patients actively receiving intravenous immunoglobulin, plasmapheresis or cytotoxic medications for thrombocytopenia

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No